APTX News and Press, Aptinyx Inc. From 11/16/21

Kezar Life Sciences (NASDAQ:KZR) +46% on phase 2 data for lupus candidate Axon Enterprise (NASDAQ:AXON) +24% on Q3 results Cyclo Therapeutics (NASDAQ:CYTH) +19% on Q3 results. Comstock Holding Companies (NASDAQ:CHCI) +20% on Q3 results. Romeo Power (NYS...

The following slide deck was published by Aptinyx Inc. in conjunction with their 2021 Q3 earnings call. For further details see: Aptinyx Inc. 2021 Q3 - Results - Earnings Call Presentation

Image source: The Motley Fool. Aptinyx Inc. (NASDAQ: APTX) Q3 2021 Earnings Call Nov 09, 2021 , 5:00 p.m. ET Operator Continue reading For further details see: Aptinyx Inc. (APTX) Q3 2021 Earnings Call Transcript

Aptinyx Brands, Inc. (APTX) Q3 2021 Earnings Conference Call November 09, 2021, 17:00 ET Company Participants Patrick Flavin - Senior Manager, Corporate Development and Investor Relations Norbert Riedel - CEO & Director Andrew Kidd - President & COO Ashish Khanna - CFO & Chief Bus...

Aptinyx (NASDAQ:APTX): Q3 GAAP EPS of -$0.31 in-line. Cash Position: Cash and cash equivalents of $125.3M. Press release For further details see: Aptinyx Q3 EPS in-line

Completed enrollment in Phase 2b study of NYX-2925 in patients with painful diabetic peripheral neuropathy; results expected in early to mid 2Q 2022 Phase 2b fibromyalgia study and exploratory Phase 2 cognitive impairment study remain on track for readouts in 2022 PTSD...

Results from the Phase 2b study are expected in early to mid 2Q 2022 Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced the completion of enrollm...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the company will host a conference call and live webcast on Tuesday, November 9, 2021 at 5:00 p.m. ET...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today announced the appointment of Gilmore O’Neill, M.B., M.M.Sc., to the company’s board of directors. Dr. O’N...

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Norbert Riedel, Ph.D., chief executive officer, will participate in a fireside chat at the 2021 Canto...